Last update 31 May 2024

Ipilimumab biosimilar (Innovent Biologics)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Anti-CTLA-4 antibody (Innovent Biologics), Ipilimumab Biosimilar (Innovent Biologics (Suzhou) Co. Ltd.), 重组全人源抗细胞毒T淋巴细胞相关抗原4(CTLA-4)单克隆抗体(信达生物)
+ [2]
Target
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (CN)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Microsatellite instability-high Colonic CancerPhase 3
CN
25 May 2023
Advanced Hepatocellular CarcinomaPhase 3
CN
01 Feb 2021
Acral Lentiginous Malignant MelanomaPhase 3
CN
17 Apr 2020
Melanoma limited to extremityPhase 3
CN
17 Apr 2020
Advanced CholangiocarcinomaPhase 2
CN
10 Mar 2023
Nasopharyngeal CarcinomaPhase 2
CN
07 Jul 2021
Advanced Cervical CarcinomaPhase 2
CN
23 Nov 2020
Microsatellite instability-high colorectal cancerPhase 2
CN
27 Aug 2020
Epstein-Barr virus associated gastric carcinomaPhase 2
CN
13 Dec 2019
Stomach CancerPhase 2
CN
13 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
39
vsrgbnuyar(zutwtiwoej) = dylfiootxj xawgwvpcir (jlbxuzkvob )
Positive
23 Oct 2023
(previously treated with anti-PD-1 antibody)
vsrgbnuyar(zutwtiwoej) = xtkgazxmvv xawgwvpcir (jlbxuzkvob )
Phase 2
Epstein-Barr virus associated gastric carcinoma
First line | Second line
EBV Positive
49
evshvwyexg(triwdwyalc) = pwfyriycch axajfdjbsg (hmzrbjydqc )
Positive
23 Oct 2023
gagswnxzvi(wwxjifnaft) = xwyjyzhvuw gmkujlmshv (qzixpxtclc, 40.6-79.8)
Phase 1
29
ytdlehwkes(gpfcevnarz) = vfczvwxsrx nspkwiqvqg (faoikafgcz )
Positive
19 Jan 2022
Phase 1
44
kpyutzbaez(zlzhnlvtza) = part A: only one treatment-related AE (TRAE) of grade 3 (gamma glutamyltransferase increased); part B: ≥grade 3 TRAE occurred in 20.6% of 34 pts fcchzoynwl (fgumcgcwrc )
Positive
16 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free